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Background: To assess the prevalence of cannabis use and dependence in a popula-
tion of schizophrenic inpatients and to compare schizophrenics with and without cannabis
consumption.
Methods: One hundred one schizophrenic patients were examined during their first week
of hospitalization. They answered the PANNS scale of schizophrenia, the CAGE and the
Fagerström questionnaire, and the DSM-IV-TR criteria for cannabis, alcohol, opiates, and
nicotine use dependence were checked.We also assessed socio-demographic characteris-
tics, the motive of cannabis consumption, and the number of cannabis joints and alcoholic
drinks taken.
Results: The prevalence of cannabis consumption was 33.6% among schizophrenic inpa-
tients. Schizophrenics consuming cannabis were younger than non-schizophrenics (33.3
vs. 44.7 years p<0.0001), more often male (77 vs. 54%, p=0.02) and had been hospital-
ized for the first time in psychiatry earlier (24.3 vs. 31.3 p=0.003). Eighty-eight percent of
cannabis consumers were dependent on cannabis. They were more often dependent on
opiates (17 vs. 0%) and alcohol (32 vs. 7.4%, p=0.001) and presented compulsive buying
more often (48 vs. 27%, p=0.04). Logistic regression revealed that factors associated
to cannabis consumption among schizophrenics were cannabis dependence, male gen-
der, pathological gambling, opiate dependence, number of joints smoked each day, and
compulsive buying.
Conclusion: 33.6% of the schizophrenic patients hospitalized in psychiatry consume
cannabis and most of them are dependent on cannabis and alcohol. Hospitalization in
psychiatry may provide an opportunity to systematically identify a dependence disorder
and to offer appropriate information and treatment.
Keywords: cannabis, addiction, dependence, alcohol, nicotine, compulsive buying, pathological gambling, alcohol
dependence
INTRODUCTION
Reported prevalence of substance use disorders in people suffer-
ing from schizophrenia ranges from 10 to 70% according to the
assessment methods (1). Cannabis, the most frequently used illicit
drug of the western world, is the preferred substance of patients
with schizophrenia (2). Lifetime use of cannabis among schizo-
phrenics is twice as high in the general population (1) and about
one-quarter of schizophrenics have a lifetime cannabis use disor-
der (3). The use of psychoactive substances such as cannabis could
be a form of self-medication in an attempt to mitigate symp-
toms and or to reduce side effects of the antipsychotic medication
(2). Whether cannabis use is or not an etiological or precipitat-
ing factor of psychotic episodes is still in debate but cannabis
seems to be at least a component cause in the development of
schizophrenia (4).
Cannabis use is especially detrimental to people with schiz-
ophrenia (5, 6). It is associated with earlier onset of psy-
chosis and with treatment-resistant forms of schizophrenia (7).
Cannabis-using schizophrenics show higher relapse rates, have
less access to non-pharmacological interventions, and need longer
hospitalizations (8).
MATERIALS AND METHODS
Our work does not address the role of cannabis in the develop-
ment of schizophrenia but is focused on the comparison between
schizophrenics with and without cannabis consumption.
We try to answer the three following questions:
Can we confirm the high prevalence of cannabis use and depen-
dence in a population of French schizophrenic patients? For this
purpose we assessed the frequency of cannabis consumption and
dependence among a population of schizophrenic inpatients.
Do schizophrenic consuming cannabis present more severe social
problems and are they more often hospitalized? We compared
socio-demographic characteristics and psychiatric history of
schizophrenics with or without cannabis.
Can cannabis consumption be understood as a self-medication for
symptoms of schizophrenia or as a self-treatment for side effects of
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medications? We tried to indirectly answer this question by ask-
ing patients about their motivation for cannabis consumption.
We wanted to know if they used cannabis to alleviate anxiety or
hallucinations or by boredom. In order to know if cannabis con-
sumption is associated to more severe forms of schizophrenia,
we compared severity of schizophrenia, anxiety, or depression
among patients with and without cannabis consumption.
Due to its cross-sectional design, our work does not address the
role of cannabis in the development of schizophrenia. It is focused
on the effect of continuous use on symptoms of patients already
suffering from schizophrenia.
The study was reviewed and approved by the ethical review
board of the department of psychiatry and addictive medi-
cine from Bichat (AP-HP) hospital. To ensure confidentiality, all
identifying data were removed and all records were kept locked.
INCLUSION CRITERIA
To be eligible, patients had to be between 18 and 65 years of age,
able to understand the informed consent procedure and meet the
DSM-IV-R criteria for schizophrenia. We proposed the question-
naire to all consecutive schizophrenic patients admitted in the
same department of psychiatry during the 12 months of the study.
STUDY DESIGN AND RECRUITMENT
The study was conducted in the Bichat Maison Blanche Depart-
ment of Psychiatry. This department is located in a Parisian Uni-
versity Hospital, which serves the North of Paris (France). Patients
were not pre-selected and they strictly reflected patients usually
admitted. In our practice, patients are only hospitalized when their
behavior is a risk factor for themselves or for society. Hospitalized
patients have often rejected regular care and pharmacotherapy.
Patients at the time of the assessment were in regular treatment
or had just started treatment. All patients were interviewed by a
psychiatrist (Michaelle Ilongo) or a psychologist (Anne Basquin)
trained to use the study instruments. Patients were assessed during
their first week of stay in the department. Recruitment covered
a 1-year period (2011). Assessment consisted in two sessions of
1 h with structured interviews. All patients could sustain their
attention during the two sessions. Diagnosis of schizophrenia was
confirmed with the Mini International Neuropsychiatric Inter-
view (MINI) (9), which checks the DSM-IV diagnostic criteria. All
patients included fulfilled the DSM-IV criteria for schizophrenia.
SOCIO-DEMOGRAPHICS
We assessed demographic details (age, working status, marital
status) and modalities of hospitalization through a specific and
validated questionnaire (10).
PSYCHIATRIC SYMPTOMS
Psychotic symptoms were studied with the Positive and Nega-
tive Symptom Scale (PANSS) (11, 12). Special attention was given
to the items of the PANSS sub-scores of positive and negative
symptoms. We assessed depression with the Montgomery–Asberg
Depression Rating Scale (MADRS) (13). This scale is a 10-item
clinician-rated scale measuring severity of depressive symptoms.
Items are rated on a seven-point Likert scale (from 0 to 6) and
the total score ranges from 0 to 60. The Hamilton Anxiety Rating
Scale (14) provides an overall measure of global anxiety, including
psychic (cognitive) and somatic symptoms.
SUBSTANCE USE
Our first question was “did you smoke cannabis in the last 7 days
prior to admission to the hospital?” Patients who answered pos-
itively to this question were included in the “cannabis +” group
and compared to those who had not smoked during the last 7 days
“cannabis−” group. To pursue the assessment of cannabis use dis-
orders, we checked the DSM-IV-R criteria for cannabis abuse and
dependence and used a specific questionnaire to quantify the num-
ber of joints smoked each day and the number of days per week
in which patients smoked cannabis (15). In order to approach
motives of cannabis consumption, we proposed to all patients six
analogic visual scales. We asked them to score between 0 (I do
not agree at all with this proposition) and 10 (I fully agree with
this proposition) their answer to the following questions: I take
cannabis to relax, to have a wild time, from force of habit, by
boredom, to get stimulated, or to take away hallucinations.
Cigarette smoking was studied with the Fagerström question-
naire (16). This test contains four yes–no and two multiple-choice
questions. The average score in randomly selected smokers is
approximately 4–4.5. In samples of cigarette smokers seeking treat-
ment, mean scores range from 5.2 to 6.3 (16). The DSM-IV-R
criteria for nicotine dependence were also checked and we calcu-
lated the number of cigarettes smoked each day during the week
before admission.
All patients answered the Cut–Annoyed–Guilty–Eye (CAGE)
Opener questionnaire (17) to characterize their relation to alco-
hol. Item responses of the CAGE are scored 0 or 1. A total score of 2
or more is considered clinically significant. The quantity of drinks
taken within a 24-h period during the last week was assessed with
a specific questionnaire previously validated (15) – a drink being
defined as the amount of alcohol (about 10 g) found in 300 ml of
beer, 100 ml of wine, or 25 ml of whiskey. The number of drinking
days per week in the month before the interview was also quan-
tified. We measured the number of daily drinks from Monday to
Thursday and the number of drinks at the end of the week (Fri-
day to Sunday). We finished by checking the DSM-IV-R criteria
for alcohol dependence. To identify other uses of illicit drug, we
asked patients about their opiates and cocaine consumption and
we checked the DSM-IV-R criteria of dependence for these two
substances.
PATHOLOGICAL GAMBLING AND COMPULSIVE BUYING
In addition to dependence to psychoactive substance, we also
studied two frequent forms of behavioral addiction: pathological
gambling and compulsive buying. We used a specific question-
naire (18) to assess compulsive buying. The 19 items (questions
with yes–no answers) represent major basic features of compulsive
buying: impulsivity, urges to shop and buy, emotions typically felt
before, during, and after purchase, post purchase guilt and regrets,
degree of commitment to short-term gratification, tangible conse-
quences of buying, and avoidance strategies. Subjects with a score
superior to nine are considered compulsive buyers. Pathological
gambling was diagnosed according to the DSM-IV-R criteria. We
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checked the diagnostic criteria with a questionnaire previously
validated (15).
ANALYSIS OF DATA
For all data, we compared schizophrenic patients with or with-
out cannabis consumption in the last 7 days (cannabis + and −
groups). Differences between cannabis+ and− groups were tested
with Analysis of Variance (ANOVA) and with the Student’s t -test
for quantitative parameters. We used theχ2 test to compare quali-
tative parameters. Predictive factors of the presence of cannabis
consumption were also identified with multinomial regression
analysis. The group without cannabis consumption was chosen
as reference category for logistic regression. All statistical tests
were two-tailed and a p value of 0.05 or less was considered to
be significant.
RESULTS
We proposed the questionnaires to 145 consecutive schizophrenic
patients admitted in the same department of psychiatry. Forty-
four patients were not included in the study and 101 filled the
questionnaires. Among the patients not included, 20 were unable
to understand the study as a result of cognitive disabilities and 22
were too agitated or aggressive to fill the questionnaires. Thirty-
four from the 101 patients (33.6%) included in the study had
consumed cannabis in the week preceding the hospitalization.
Out of these 101 patients, 39 were female (Table 1). Mean
age was 40.9 years. As expected, cannabis consumption was much
more prevalent in males (77% of men among the cannabis+ group
vs. 54% in the cannabis − group). Patients from the cannabis
+ group were younger (33.3 vs. 44.7 years, p< 0.0001), more
often male (77 vs. 54%, p= 0.02) and more often unemployed
(91 vs. 72%, p= 0.03). The age of their first hospitalization in a
psychiatric department was younger (24 vs. 31.3 years, p= 0.003).
Unsurprisingly, as seen on Table 2, schizophrenics from the
cannabis+ group were more often dependent on cannabis (88 vs.
0%). They presented more often opiate dependence (17 vs. 0%),
alcohol dependence (32 vs. 7.4%, p= 0.001). They drank more
alcohol (5.4 vs. 1.3 drinks/day). The number of drinking days/week
in the last month was higher in the cannabis + group (3.3 vs. 1.6
drinks p= 0.005). Their mean CAGE scores were higher (1.6 vs.
0.6, p< 0.001). None of the patients consumed cocaine. Preva-
lence of nicotine dependence was equivalent in the two groups
(60 vs. 58%). The number of cigarettes smoked each day was also
equivalent (10.7 vs. 9.6). Patients from the cannabis + group had
higher scores of compulsive buying (5.4 vs. 3.1, p= 0.01) and pre-
sented diagnostic criteria of compulsive buying more often (48 vs.
27%, p= 0.04).
We did not see (Table 3) differences between the cannabis+ and
− group in terms of symptoms of schizophrenia as assessed with
the PANNS. Global functioning was equivalent in the two groups
and schizophrenics smoking cannabis were not more depressed
or anxious than non-smokers. The most frequent motives for
cannabis consumption (Table 4) were “to relax,” “to have a wild
time,” and “from force of habit.”
Logistic regression (Table 5) showed that cannabis consump-
tion was significantly associated to the diagnostic of cannabis
dependence, male gender, pathological gambling, opiates depen-
dence, number of joints smoked each day, and compulsive buying.
DISCUSSION
MAIN FINDINGS
Cannabis consumption is frequent among French schizophrenic
inpatients
Cannabis was the second psychoactive substance most often con-
sumed (34 patients, 33.6%) after nicotine and at the same rate
as alcohol in our population of patients. The other psychoactive
substances consumed were nicotine (59%), alcohol (33%), and
opiates (6, 5%).
Socio-demographic characteristics of schizophrenics smoking
cannabis are specific
Schizophrenics from the cannabis + group were younger. They
had been hospitalized for the first time in psychiatry at a
younger age. Only a prospective study could confirm that cannabis
Table 1 | Comparison of schizophrenic patients with and without cannabis consumption: socio-demographic characteristics, access to
hospitalization, and duration of hospitalization.
Variable Cannabis + Cannabis − Total Statistics
N =34 N =67 N =101
Age (mean, SD) 33.3 (8) 44.7 (16) 40.9 (15) Student t =38, df=99, p<0.0001
Sex (N and % of women) 8 (23%) 31 (46%) 39 (38%) χ2=4.9, df=1, p=0.027
Living alone (N and %) 22 (64%) 47 (70%) 69 (68%) χ2=0.3, df=1, p=0.578
Working (N and %) 3 (9%) 19 (28%) 22 (21%) χ2=5.05, df=1, p=0.025
ACCESSTO HOSPITALIZATION (N AND %)
Ambulance 13 (38%) 27 (40%) 40 (39%) χ2=8.7, df=3, p=0.03
Family 2 (6%) 17 (25%) 19 (18%)
Police 8 (23%) 14 (21%) 22 (21%)
Alone 11 (32%) 9 (20%) 20 (19%)
Age of first hospitalization in psychiatry (mean, SD) 24 (6.6) 31.3 (13.4) 28.8 (11.9) Student t =3, df=99, p=0.003
Months of hospitalization in psychiatry (mean, SD) 9.2 (9.3) 17.1 (23.3) 14.4 (19) Student t =1.9, df=99, p=0.06
Bold font indicates statistically significant difference.
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Table 2 | Comparison of addictive disorders among schizophrenic patients with and without cannabis consumption.
Variable Cannabis + Cannabis − Total Statistics
N =34 N =67 N =101
Alcohol consumption (N and %) 16 (55%) 18 (25%) 34 (33%) χ2=84, df=1, p=0.004
Drinks of alcohol/day during week days (mean, SD) 2.64 (4.9) 0.43 (1.2) 1.1 (3.1) Student t =−3.5, df=99, p=0.001
Drinks of alcohol/day at week-ends (mean, SD) 2.4 (3.8) 0.53 (1.3) 1.1 (2.6) Student t =−3.7, df=99, p<0.0001
Number of drinking days/week (mean, SD) 3.3 (3) 1.6 (2.6) 2.2 (2.8) Student t =−2.8 p=0.005
Alcohol dependence (N and %) 11 (32%) 5 (7.4%) 16 (15%) χ2=10.4, df=1, p=0.001
CAGE score (mean, SD) 1.6 (1.1) 0.6 (1.1) 1.1 (1.2) Student t =−4, df=99, p<0.001
Nicotine dependence (N and %) 21 (60%) 39 (58%) 60 (59%) χ2=0.23, df=1, p=0.6
Cigarettes/day (mean, SD) 10.7 (9.5) 9.6 (8.7) 10.1 (8.9) Student t =−0.55, df=99, p=0.57
Fagerström score (mean, SD) 5.5 (2.2) 5.2 (2.1) 5.4 (2.2) Student t =−0.2, df=99, p=0.7
Joints/day (mean, SD) 3.35 (3.8) 0.05 (0.2) 1.1 (2.7) Student t =−7, df=99, p<0.0001
Days/week smoking cannabis (mean, SD) 4.4 (1.1) 0.28 (0.6) 1.6 (2.1) Student t =−22.6, df=99, p<0.0001
Years of cannabis consumption (mean, SD) 12 (6.6) 0.5 (1.5) 4.6 (6.6) Student t =−14.6, df=99, p<0.0001
Cannabis dependence (N and %) 30 (88%) 0 30 (29%) χ2=84, df=1, p<0.0001
Opiate dependence (N and %) 6 (17%) 0 6 (5%) χ2=12.5, df=1, p<0.0001
Pathological gambling (N and %) 4 (11%) 2 (2.9%) 6 (5%) χ2=−0.5, df=1, p=0.56
Scores of compulsive buying (mean, SD) 5.4 (4.8) 3.1 (3.8) 3.9 (4.1) Student t =−2.5, df=99, p=0.01
Diagnostic of compulsive buying (N and %) 16 (48%) 18 (27%) 33 (32%) χ2=41, df=1, p=0.04
Bold font indicates statistically significant difference.
Table 3 | Comparison of psychiatric symptoms among schizophrenic patients with and without cannabis consumption.
Variable Cannabis + Cannabis − Total Statistics
N =34 N =67 N =101
PANNS total score (mean, SD) 33.4 (9.7) 33.4 (10.1) 33.4 (9.5) Student t =−0.001, df=99, p=0.9
PANNS sub-score of positive symptoms (mean, SD) 20.1 (7.7) 22.2 (7.4) 21.5 (7.5) Student t =1.2, df=99, p=0.2
PANNS sub-score of negative symptoms (Mean, SD) 17.5 (6.2) 18.1 (8.3) 17.9 (7.5) Student t =0.35, df=99, p=0.72
Global assessment of functioning (mean, SD) 49 (11) 51 (13) 50.4 (12.4) Student t =0.8, df=99, p=0.4
MADRS score of depression (mean, SD) 11.4 (8.3) 9.2 (8.1) 9.9 (8.2) Student t =−1.2, df=99, p=0.2
Hamilton score of anxiety (mean, SD) 11.5 (7.5) 10.5 (9.3) 10.8 (8.6) Student t =0.5, df=99, p=0.56
Table 4 | Motives of cannabis consumption (mean scores and SD).
To relax: 6.2 (3.4)
To have a wild time: 4.4 (3.7)
From force of habit: 3.8 (3.5)
By boredom: 3.2 (3.1)
To get stimulated: 2.7 (3.2)
To take away hallucinations: 2.5 (3.7)
consumption induces an earlier apparition of psychotic symp-
toms. Another difference between the cannabis + and − groups
concerns the sex ratio. Proportion of male was higher in the
cannabis+ group.
Cannabis consumption is often part of a poly addictive disorder
Cannabis consumption is highly associated to cannabis depen-
dence. Eighty-eight percent of patients consuming cannabis were
dependent of this substance. The number of joints smoked by day
is also associated in the logistic regression analysis. In the cannabis
+ group, alcohol consumption was higher and more frequent in
week days and at week-ends. Even behavioral dependence like
compulsive buying is more frequent in schizophrenics who smoke
cannabis. This observation of an association between compulsive
buying and chemical addictions was demonstrated among patients
examined in emergency or in depressed patients (18). It had never
been shown in schizophrenics. We observed another association
between cannabis consumption and another behavioral depen-
dence: pathological gambling. At our knowledge, this association
has not been previously reported. These two associations could be
an incitation to more systematically assess behavioral addictions
among schizophrenics who smoke cannabis. Nicotine was the only
psychoactive substance consumed in an equivalent proportion in
the cannabis + and − groups. The level of consumption of nico-
tine was however high in both groups (60 and 58% in the cannabis
+ and− group, respectively).
Cannabis consumption is not associated to higher severity of
psychiatric symptoms
We did not find a difference in psychiatric symptoms between
the cannabis + and − groups. Patients from both groups had
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Table 5 | Logistic regression assessing factors associated to cannabis
consumption.
Variable Odd ratio Range p
Cannabis abuse or dependence 235 5–5700 0.005
Male gender 2.9 0.3–27 0.3
Pathological gambling 1.7 0.6–47 0.7
Opiates dependence 1.66 0.5–98 0.06
Joints/day 1.52 1–2 0.04
Compulsive buying 1.5 0.6–47 0.7
Reference category: schizophrenia with cannabis consumption likehood
ratio=131, df=12, p<0.0001.
equivalent levels of depression, anxiety, negative, and positive
symptoms of schizophrenia. Since our study is cross-sectional,
we cannot conclude to an absence of effect of these symptoms.
We can only observe the lack of difference. Study of motives for
smoking does not corroborate the hypothesis of cannabis use as
a “self-treatment” of psychotic symptoms. It does not incite, in
clinical practice to authorize cannabis consumption as a way of
alleviating negative and/or positive symptoms of schizophrenia.
The motive of cannabis smoking less often cited by patients is “to
take away hallucinations” and the most often chosen is “to relax.”
A limitation of the interpretation of this result is related to the
fact that all patients, whether or not they were cannabis smoker,
were hospitalized and treated. Hypothesis can be raised that their
treatments may have hidden differences in psychotic, depressive,
or anxious symptoms.
LIMITATIONS OF THE STUDY
One of the principal limitations of the study is the exclusion of
patients unable to answer the questionnaire because of the sever-
ity of their psychiatric state. Patients most severely affected were
thus not included and their relation to cannabis was not identified.
Another limitation is linked to the method of the study. Due to
its cross-sectional design, our study does not address the impor-
tant question of the potential role of cannabis in the apparition of
schizophrenia. Only a prospective study could tell us if cannabis
has or not a direct impact on schizophrenia severity and evolu-
tion. Our study, in addition, relies only on self-declarations of the
patients. No biological assessment was performed to confirm dec-
larations of patients regarding psychoactive substances consump-
tion. Previous works (19) showed that patients with schizophrenia
underreport their consumption of alcohol and cannabis. Up to
52% of patients deny their consumption when their declarations
are compared to biological measures. We tried however to reduce
this bias of underreporting by using standardized questionnaires.
Moreover, our observed prevalence rate for cannabis consumption
is equivalent to those from other studies, which confirmed clinical
assessment with a biological measure (2). In spite of all its limita-
tions, this study is the only work that has simultaneously assessed
symptoms and severity of schizophrenia, anxiety, depression, and
all dependence disorders to psychoactive substance and behavior
(pathological gambling, compulsive buying).
In the naturalistic setting of our study most people who
use cannabis make joints that contain cannabis and tobacco in
differing compositions and of different strength (2). Besides Delta-
9-Tetra-Hydro-Cannabinol (∆-9-THC), the component that may
have psychogenic properties, cannabis contains more than 60 other
psychoactive substances, some of which possibly interfere with or
even antagonize each other. We thus compare patients with differ-
ent levels of intoxications even when they take the same number
of joints by day. Another limitation concerns our study of nicotine
consumption. We assessed nicotine dependence and nicotine con-
sumption. We did not identify patients with nicotine consumption
without dependence. The generalization of our results must also
be limited since they are drawn from a relatively small population
(101 subjects), all examined in the same hospital from the north
of Paris.
Implication of the results for prevention and public health
The main finding of our research is the high prevalence of cannabis
use and dependence among schizophrenics and the fact that this
disorder is often unrecognized and under-treated. This obser-
vation is an incitation to systematically assess cannabis depen-
dence and other forms of chemical and behavioral dependence
in patients hospitalized for schizophrenia. In the majority of
cases, dependence disorder is not recognized and patients neither
receive a treatment nor information for their comorbid addic-
tion. In the worse cases, cannabis consumption is tolerated by
psychiatric departments, which wrongly consider this substance
as a way for patients to cope with their disease and medica-
tion side effects. Schizophrenic patients must be directly asked
about their relation to cannabis, and if the diagnosis of abuse
or dependence is established, addictive disorders and co-existing
psychiatric disorders should be addressed synchronously rather
than sequentially (20). None of the patients identified as cannabis
dependent had asked for specific help in the domain of addiction
before being diagnosed by our systematic intervention. If they
had not been assessed, they would have left the department of
psychiatry with no treatment or information on the possibilities
of help.
The time of hospitalization in psychiatry provides the only
opportunity to receive information (5) and to begin to benefit from
adequate treatment. It could be a teachable moment for a propo-
sition of treatment for alcohol dependence regularly associated to
cannabis dependence. Matthew Koola et al. (5) showed in a popu-
lation of schizophrenics from Baltimore that 95.8% of them used
quitting strategies to maintain abstinence from cannabis. The most
commonly used quitting strategies were getting rid of cannabis
(72%), getting rid of cannabis paraphernalia (67%), stopped asso-
ciation with people who smoke cannabis (62%) and no longer
frequenting places where cannabis was smoked (61%). A brief
motivational help on their cannabis consumption could also be
proposed to patients with equivalent modalities of those proposed
for alcohol dependents (20, 21).
CONCLUSION
Cannabis consumption is frequent among schizophrenic patients
hospitalized in psychiatry (33.6%). Typical schizophrenic patient
at risk for cannabis consumption and dependence is a young
man, who smokes, drinks, and is unemployed. Cannabis con-
sumption is often associated to dependence to cannabis and
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other psychoactive substances (alcohol, opiates) at the excep-
tion of nicotine dependence equivalent among cannabis smok-
ers and non-smokers. Behavioral dependence like compulsive
buying is also more frequent among schizophrenics smoking
cannabis. Systematic assessment and recognition of cannabis con-
sumption must be performed during hospitalization of schizo-
phrenic patients. Early assessment of cannabis dependence enables
a better evolution of both psychotic and addictive disorders.
Hospitalization may provide an opportunity to offer informa-
tion and treatment for this frequent addictive disorder. Fur-
ther prospective studies are needed to confirm the impact of
cannabis consumption and use disorders on the evolution of
schizophrenia.
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